MeiraGTx Holdings plc entered into an Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. to sell and assign certain assets related to a gene therapy product, with an upfront cash purchase price of $65,000,000 and future contingent consideration of up to $350,000,000.